Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02016781 · ClinicalTrials.gov registry record · Phase 2
Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)
A Phase 2 study, sponsored by Medical College of Wisconsin.
- Completed
- Registry status
- Phase 2
- Development phase
- 384
- Enrollment target
NCT02016781: Completed Phase 2 study, sponsored by Medical College of Wisconsin.
NCT02016781 is a Phase 2 study that has completed, run by Medical College of Wisconsin. The registered enrollment target is 384 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (189% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02016781, a Phase 2 study, has completed, sponsored by Medical College of Wisconsin.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 384 participants
- Enrollment target
Study Summary
This study is designed as a multicenter trial, with biological assignment to one of two study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
Primary Outcome
The primary endpoint for this study is overall survival (OS) at three years post-consent. Death from any cause will be considered an event for this endpoint. Surviving participants are censored at the time of last follow-up. Three year OS estimates are adjusted for age, race/ethnicity, performance status, IPSS score, duration of disease, and response to prior hypomethylating therapy. The results posted are from the February 2020 interim analysis per protocol study design. Two interim analyses fo
Interventions
- PROCEDURE Allogeneic Hematopoietic Cell Transplant
- PROCEDURE Hypomethylating Therapy / Best Supportive Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 384 participants |
| Start Date | 2013-12-16 |
| Est. Completion | 2021-10-05 |
| Phase | Phase 2 |
What the finished NCT02016781 record still lists
NCT02016781 is an interventional study that assigns participants to a tested intervention. The registered 384 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (189% higher).
The record links to 0 conditions, and to 2 interventions - of which Allogeneic Hematopoietic Cell Transplant is the first listed.
NCT02016781 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02016781 about?
NCT02016781 is a clinical study titled "Allo vs Hypomethylating/Best Supportive Care in MDS (BMTCTN1102)". This study is designed as a multicenter trial, with biological assignment to one of two study arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation (RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
What is the current status of trial NCT02016781?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 384 participants. The study started on 2013-12-16. Estimated completion is 2021-10-05.
What interventions are being tested in trial NCT02016781?
The interventions under investigation include: Allogeneic Hematopoietic Cell Transplant (PROCEDURE), Hypomethylating Therapy / Best Supportive Care (PROCEDURE).
Who is sponsoring clinical trial NCT02016781?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02016781's enrollment target sits among peer trials
384 111th of 2000 higher than 1,890 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06277661 · 384 participants · NA
The Mom and Infant Outcomes (MOMI) Study
- NCT06372964 · 384 participants · Phase 3
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
- NCT06501040 · 384 participants · NA
Increasing Knowledge and Interest in Cancer Clinical Trials
- NCT06566703 · 384 participants · NA
Testing ANSOS for Efficacy in Multi-Tribal Urban Communities
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI